Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

In silico prediction of drug-target interaction networks based on drug chemical structure and protein sequences.

Li Z, Han P, You ZH, Li X, Zhang Y, Yu H, Nie R, Chen X.

Sci Rep. 2017 Sep 11;7(1):11174. doi: 10.1038/s41598-017-10724-0.

2.

Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.

Zhang M, Schmitt-Ulms G, Sato C, Xi Z, Zhang Y, Zhou Y, St George-Hyslop P, Rogaeva E.

PLoS One. 2016 Dec 22;11(12):e0168812. doi: 10.1371/journal.pone.0168812. eCollection 2016.

3.

Large-scale identification of adverse drug reaction-related proteins through a random walk model.

Chen X, Shi H, Yang F, Yang L, Lv Y, Wang S, Dai E, Sun D, Jiang W.

Sci Rep. 2016 Nov 2;6:36325. doi: 10.1038/srep36325.

4.

DPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein Interactome.

Luo H, Zhang P, Cao XH, Du D, Ye H, Huang H, Li C, Qin S, Wan C, Shi L, He L, Yang L.

Sci Rep. 2016 Nov 2;6:35996. doi: 10.1038/srep35996.

5.

Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer.

Ma Y, Hou L, Yu F, Lu G, Qin S, Xie R, Yang H, Wu T, Luo P, Chai L, Lv Z, Peng X, Wu C, Fu D.

Oncotarget. 2017 Mar 14;8(11):18417-18423. doi: 10.18632/oncotarget.12813.

6.

Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.

Wu M, Yu Q, Li Q.

Oncotarget. 2016 Dec 13;7(50):82074-82084. doi: 10.18632/oncotarget.12617.

7.

DASPfind: new efficient method to predict drug-target interactions.

Ba-Alawi W, Soufan O, Essack M, Kalnis P, Bajic VB.

J Cheminform. 2016 Mar 16;8:15. doi: 10.1186/s13321-016-0128-4. eCollection 2016.

8.

Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.

Shu M, Zai X, Zhang B, Wang R, Lin Z.

PLoS One. 2016 Jan 19;11(1):e0147048. doi: 10.1371/journal.pone.0147048. eCollection 2016.

9.
10.

Anchor-based classification and type-C inhibitors for tyrosine kinases.

Hsu KC, Sung TY, Lin CT, Chiu YY, Hsu JT, Hung HC, Sun CM, Barve I, Chen WL, Huang WC, Huang CT, Chen CH, Yang JM.

Sci Rep. 2015 Jun 16;5:10938. doi: 10.1038/srep10938.

11.

Drug repositioning for diabetes based on 'omics' data mining.

Zhang M, Luo H, Xi Z, Rogaeva E.

PLoS One. 2015 May 6;10(5):e0126082. doi: 10.1371/journal.pone.0126082. eCollection 2015.

12.

FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach.

Lu W, Cheng F, Jiang J, Zhang C, Deng X, Xu Z, Zou S, Shen X, Tang Y, Huang J.

Sci Rep. 2015 Jan 29;5:8114. doi: 10.1038/srep08114.

13.

Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study.

Su J, Chang C, Xiang Q, Zhou ZW, Luo R, Yang L, He ZX, Yang H, Li J, Bei Y, Xu J, Zhang M, Zhang Q, Su Z, Huang Y, Pang J, Zhou SF.

Drug Des Devel Ther. 2014 Dec 12;8:2555-602. doi: 10.2147/DDDT.S73476. eCollection 2014.

14.
15.

Automatic construction of a large-scale and accurate drug-side-effect association knowledge base from biomedical literature.

Xu R, Wang Q.

J Biomed Inform. 2014 Oct;51:191-9. doi: 10.1016/j.jbi.2014.05.013. Epub 2014 Jun 10.

16.

DDI-CPI, a server that predicts drug-drug interactions through implementing the chemical-protein interactome.

Luo H, Zhang P, Huang H, Huang J, Kao E, Shi L, He L, Yang L.

Nucleic Acids Res. 2014 Jul;42(Web Server issue):W46-52. doi: 10.1093/nar/gku433. Epub 2014 May 29.

17.
18.

APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia.

Song X, Li X, Gao J, Zhao J, Li Y, Fan X, Lv L.

PLoS One. 2014 Apr 7;9(4):e93902. doi: 10.1371/journal.pone.0093902. eCollection 2014.

19.

Interaction network among functional drug groups.

Lee M, Park K, Kim D.

BMC Syst Biol. 2013 Oct 16;7 Suppl 3:S4. doi: 10.1186/1752-0509-7-S3-S4.

20.

Controllability in cancer metabolic networks according to drug targets as driver nodes.

Asgari Y, Salehzadeh-Yazdi A, Schreiber F, Masoudi-Nejad A.

PLoS One. 2013 Nov 25;8(11):e79397. doi: 10.1371/journal.pone.0079397. eCollection 2013.

Supplemental Content

Support Center